Timmermann W, Calne R Y, White D J, White D, Thiede A
Chir Forum Exp Klin Forsch. 1980:139-43.
The new immunosuppressive substances Cyclosporin A (group A = 15 mg) and Cytimun = ASTA 5122 (group B = 15 mg, group C = 5 mg) were tested in rats that received accessory cervical heart transplants. A syngeneic (DA leads to DA) and a strongly allogeneic (PVG leads to DA) strain combination served as controls of operative and immunogenetic parameters. Whereas Cyclosporin A (group A) brought about a local transplant tolerance in 90% of cases, at a dosage of 15 mg/kg per day (group B), Cytimun led in 88% of cases to lethal intoxication of the recipients. At a dosage of 5 mg/kg per day (group C), 67% of the animals survived; however, they showed electrocardiographic evidence of possible temporary rejection crises between the 5th and the 13th day.
新型免疫抑制物质环孢素A(A组=15毫克)和西替明=ASTA 5122(B组=15毫克,C组=5毫克)在接受颈部辅助心脏移植的大鼠中进行了测试。同基因(DA到DA)和强异基因(PVG到DA)品系组合用作手术和免疫遗传学参数的对照。环孢素A(A组)以每天15毫克/千克的剂量在90%的病例中产生了局部移植耐受性,而西替明在88%的病例中导致受体致命中毒(B组)。在每天5毫克/千克的剂量下(C组),67%的动物存活;然而,它们在第5天至第13天之间显示出可能的暂时性排斥反应危机的心电图证据。